Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | RAB9A, member RAS oncogene family | Starlite/ChEMBL | No references |
Homo sapiens | ATPase family, AAA domain containing 5 | Starlite/ChEMBL | No references |
Homo sapiens | survival of motor neuron 2, centromeric | Starlite/ChEMBL | No references |
Homo sapiens | Niemann-Pick disease, type C1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | ras-related protein Rab-5B | RAB9A, member RAS oncogene family | 201 aa | 165 aa | 30.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | S-adenosylmethionine decarboxylase proenzyme, putative | 0.0105 | 0.0509 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0286 | 0.2468 | 1 |
Echinococcus granulosus | expressed conserved protein | 0.0112 | 0.058 | 0.0362 |
Treponema pallidum | cell division protein FtsZ | 0.0298 | 0.2599 | 0.5 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0286 | 0.2468 | 1 |
Mycobacterium ulcerans | cell division protein FtsZ | 0.0298 | 0.2599 | 0.5 |
Entamoeba histolytica | Niemann-Pick C1 protein, putative | 0.0119 | 0.0659 | 0.5 |
Echinococcus granulosus | Niemann Pick C1 protein | 0.0119 | 0.0659 | 0.0762 |
Loa Loa (eye worm) | S-adenosylmethionine decarboxylase proenzyme | 0.0105 | 0.0509 | 0.1912 |
Echinococcus multilocularis | Niemann Pick C1 protein | 0.017 | 0.1213 | 0.1213 |
Brugia malayi | Cell division protein ftsZ | 0.0143 | 0.0918 | 0.372 |
Brugia malayi | S-adenosylmethionine decarboxylase proenzyme | 0.0105 | 0.0509 | 0.2063 |
Loa Loa (eye worm) | hypothetical protein | 0.0119 | 0.0659 | 0.2528 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0286 | 0.2468 | 0.2468 |
Trypanosoma brucei | S-adenosylmethionine decarboxylase | 0.0105 | 0.0509 | 0.5 |
Schistosoma mansoni | niemann-pick C1 (NPC1) | 0.0121 | 0.0679 | 1 |
Echinococcus granulosus | Niemann Pick C1 protein | 0.017 | 0.1213 | 0.359 |
Trypanosoma cruzi | S-adenosylmethionine decarboxylase proenzyme, putative | 0.0105 | 0.0509 | 0.5 |
Brugia malayi | Niemann-Pick C1 protein precursor | 0.0119 | 0.0659 | 0.2668 |
Echinococcus multilocularis | Niemann Pick C1 protein | 0.0119 | 0.0659 | 0.0659 |
Wolbachia endosymbiont of Brugia malayi | cell division protein FtsZ | 0.0298 | 0.2599 | 0.5 |
Leishmania major | S-adenosylmethionine decarboxylase | 0.0105 | 0.0509 | 0.5 |
Brugia malayi | hypothetical protein | 0.0286 | 0.2468 | 1 |
Mycobacterium leprae | cell division protein FtsZ | 0.0298 | 0.2599 | 0.5 |
Echinococcus multilocularis | S adenosylmethionine decarboxylase proenzyme | 0.0105 | 0.0509 | 0.0509 |
Echinococcus multilocularis | expressed conserved protein | 0.0112 | 0.058 | 0.058 |
Trypanosoma brucei | S-adenosylmethionine decarboxylase | 0.0105 | 0.0509 | 0.5 |
Trypanosoma cruzi | S-adenosylmethionine decarboxylase proenzyme, putative | 0.0105 | 0.0509 | 0.5 |
Onchocerca volvulus | 0.0058 | 0 | 0.5 | |
Brugia malayi | Cell division protein ftsZ | 0.0147 | 0.0963 | 0.39 |
Mycobacterium tuberculosis | Cell division protein FtsZ | 0.0298 | 0.2599 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0029 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 3.1623 um | PUBCHEM_BIOASSAY: qHTS Assay for NPC1 Promoter Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 4.4668 um | PUBCHEM_BIOASSAY: qHTS Assay for Rab9 Promoter Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.3489 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493106, AID493143] | ChEMBL. | No reference |
Potency (functional) | = 19.9526 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 20.5878 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 20.5962 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 23.9341 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.